News

Eli Lilly’s Obesity Pill Shows Promising Weight Loss in New Results
In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...
Eli Lilly weight loss pill shows promise in latest clinical trial, company says
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body fat.
Marketplace1d
Makers of Wegovy, Zepbound face competition from compounding pharmacies
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...
Eli Lilly: The Best Growth Prospects Come At A Price
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Zacks Investment Research on MSN3d
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?
Eli Lilly and Company LLY will report its second-quarter earnings on Aug. 7, before market open. The Zacks Consensus Estimate ...